

Announcement Summary

Entity name

AROVELLA THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

Wednesday March 26, 2025

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

The options were issued as unlisted attaching options for a placement conducted in April / May 2024, and was approved at the EGM held 23 May 2024. Refer to the notice of meeting lodged 23 April 2024 and associated Appendix 3G lodged 24 May 2024 for further information. The Company is seeking to quote these options with the Company's existing quoted options, noting that the terms and conditions of those options are the same.

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
ALAO	OPTION EXPIRING 24-MAY-2027	115,897,550	26/05/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

AROVELLA THERAPEUTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

Registration number

ABN

35090987250

1.3 ASX issuer code

ALA

1.4 The announcement is

New announcement

1.5 Date of this announcement

26/3/2025



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The options were issued as unlisted attaching options for a placement conducted in April / May 2024, and was approved at the EGM held 23 May 2024. Refer to the notice of meeting lodged 23 April 2024 and associated Appendix 3G lodged 24 May 2024 for further information. The Company is seeking to quote these options with the Company's existing quoted options, noting that the terms and conditions of those options are the same.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a +disclosure document or +PDS for the +securities to be quoted



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

ALAO: OPTION EXPIRING 24-MAY-2027

Issue date

26/5/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

115,897,550

Are the +securities being issued for a cash consideration?

Nο

Please describe the consideration being provided for the +securities

April 2024 placement attaching options.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted

As approved at the EGM held 23 May 2024, the placement attaching options are exercisable at \$0.150 and expiring 36 months post issue.

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

April 2024 placement attaching options approved at the EGM held 23 May 2024.



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description

ALA : ORDINARY FULLY PAID

Total number of +securities on issue

ALAO: OPTION EXPIRING 24-MAY-2027 155,803,175

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
ALAAB : OPTION EXPIRING 17-JUN-2025 EX \$0.057	1,286,667
ALAAC : OPTION EXPIRING 17-JUN-2025 EX \$0.061	1,286,667
ALAAD : OPTION EXPIRING 17-JUN-2025 EX \$0.065	1,286,666
ALAAL : OPTION EXPIRING 24-MAY-2027 EX \$0.15	115,897,550
ALAAE : OPTION EXPIRING 10-APR-2026 EX \$0.207	4,000,000
ALAAA : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	74,531,317



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

No

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?